Rocket alignment with FDA ‘sounds reasonable,’ says Chardan

Chardan keeps a Buy rating on Rocket Pharmaceuticals (RCKT) with a $12 price target after the FDA lifted the clinical hold on company’ Phase II trial of RP-A501 in Danon disease. The trial proceeding with a lower dose “sounds reasonable” and does not involve the addition of a new regimen component with an unknown profile in Danon, the analyst tells investors in a research note. Chardan believes the completion date could be late in 2026 with a second half of 2027 readout on the 12-month primary endpoint, consistent with its 2028 launch projections.